CD37 and hematologic disorder: Incorporating tumour specific antibodies (anti-CD19, anti-CD20 and anti-CD37) achieved higher delivery and killing efficiency in primary CLL cells ex vivo which may be beneficial for targeting hematologic diseases where FTY720 induces T cell apoptosis [243].